Quantcast

Latest Etoricoxib Stories

2011-09-28 09:08:55

An updated study published in this week's PLoS Medicine gives some new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that among these commonly used drugs, naproxen and low dose ibuprofen are least likely to increase cardiovascular risk whereas diclofenac, even in doses available without prescription, elevates risk. Using only observational studies (30 case-control studies and 21 cohort studies) because randomised controlled trials...

2011-09-28 05:53:08

(Ivanhoe Newswire) — An updated study gives new information on the cardiovascular risks of non-steroidal anti-inflammatory drugs (NSAIDs) and suggests that naproxen, a commonly used drug, and low dose ibuprofen are least likely to increase cardiovascular risks. In addition, diclofenac, even doses available without prescription, elevates the risk. Using only observational studies, because randomized controlled trials have only reported small numbers of cardiovascular events, the...

88fd3279b1b6e630577ba281fadeb1c2
2011-01-12 09:25:00

A new study published in the British Medical Journal (BMJ) on Wednesday warns that taking specific types of pain relievers could increase a person's risk of suffering a stroke or other heart-related ailment. In the study, researchers from the University of Bern in Switzerland and the Swiss Agency for Therapeutic Products (Swissmedic) studied the effects of seven types of non-steroidal anti-inflammatory drugs (NSAIDs) and new generation anti-inflammatory drugs (COX-2 inhibitors)--naproxen,...

2006-11-13 12:00:18

U.S. firm Merck said Monday its new COX 2 painkiller -- in the same class as Vioxx -- has a cardiac risk similar to Novartis' Voltaren. According to data from a large patient trial released Monday, Merck said its new arthritis treatment Arcoxia (etoricoxib), carries a comparable risk of heart attack and other cardiovascular events, compared to Voltaren (diclofenac), but showed a lower risk of gastrointestinal problems, like bleeding ulcers. However, Merck said the data also revealed that...

2006-08-23 09:20:00

CHICAGO -- Merck & Co. on Wednesday said the experimental arthritis drug Arcoxia, in a study, met its main goal of causing no more blood clot-related heart attacks than a standard treatment, but more patients taking Arcoxia withdrew from the trial due to serious side effects. The trial pitted Arcoxia, the planned successor to Vioxx, against diclofenac, a widely used non-steroidal anti-inflammatory drug, among patients with osteoarthritis and rheumatoid arthritis. Vioxx was pulled off the...

2006-08-23 08:00:00

CHICAGO (Reuters) - Drugmaker Merck & Co. on Wednesday gave preliminary results of a study of its investigational painkiller Arcoxia, the planned successor to Vioxx, which was pulled off the market in 2004 after being linked to stroke and heart attack. Merck said the study, comparing Arcoxia with the anti-inflammatory drug diclofenac, found the "relative risk" of certain cardiovascular events was similar. The incidence of patients withdrawing from the study due to side effects related to...

2004-11-25 03:00:18

WHITEHOUSE STATION, NJ: The Vioxx recall has not appeared to have hurt competitor drugs that stop pain in a similar fashion, and that could spell good news for Merck's next pain product, Arcoxia. New research on doctors' prescribing habits suggests that specialists show little reluctance in continuing to prescribe painkillers belonging to the same class as Vioxx - cox-2 inhibitors. "Specialists are not going to overreact to this," said Andrea McDonough, senior director of market events at...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related